Could muscle loss predict blood cancer outcomes?
NCT ID NCT05150561
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This study is investigating how common muscle loss, known as sarcopenia, is in people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will measure body composition using DXA scans and track hospital stays, disease progression, and survival. The goal is to see if muscle loss can serve as a warning sign for poorer outcomes, which could help guide future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If muscle loss predicts outcomes, it could lead to routine screening and early nutrition or exercise support for blood cancer patients.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. Results may not apply to all blood cancer types or treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rigshospitalet
Copenhagen, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can engineered immune cells tackle brain lymphoma?